Mitsubishi Tanabe Pharma contribute funding to Global Health Innovative Technology Fund’s second phase—Targeting treatments for infectious diseases that burden the developing world—

Mitsubishi Tanabe Pharma Corporation (President and Representative Director: Masayuki Mitsuka) has endorsed the objectives of the Global Health Innovative Technology Fund (GHIT Fund) and has decided to provide 100 million yen from FY2018 through FY2022.

The GHIT Fund is a public-private partnership, originating in Japan in 2013, that advances the discovery of new drugs for infectious diseases that burden the developing world, such as malaria, tuberculosis, and neglected tropical diseases (NTDs). The GHIT Fund aims to bolster Japan’s international contribution to global health through new drug R&D capabilities that leverage the advanced scientific and technical knowledge of Japanese pharmaceutical companies and other institutions.

Mitsubishi Tanabe Pharma Corporation has already funded 40 million yen at the first period from FY2013 through FY2017.

Accordingly, Mitsubishi Tanabe Pharma Corporation provided its original pharmaceutical compound library (50,000 compounds) to Medicines for Malaria Venture (MMV), a not-for-profit research organization focused on antimalarial drugs with the support of Global Health Innovative Technology Fund. This joint research program has reached identification of promising three hit compound groups with antimalarial activity. Continuously we will move into the next stage of research focusing on these three hit compound groups as new antimalarial leads.

Through participation in the GHIT Fund, Mitsubishi Tanabe Pharma will contribute to the treatment of infectious diseases in the developing world.

〈〈For Details, Contact the Following Section〉〉
Corporate Communications Department
Tel +81-6-6205-5211